Traditional Chinese medicine (TCM) has been handed down for thousands of years. It has along history in the treatment of virus infection and has a good effect on the upperrespiratory tract infection.In recent years, the project applicant has been conducting research on the anti infectionand anti inflammation treatment of traditional Chinese medicine, and has carried out alot of clinical practice exploration in non-specific inflammation.The purpose of this research is to study the therapeutic effect of a traditional Chinesemedicine prescription on COVID-19 infection.
Not Provided
Drug: Traditional Chinese Medicine Formulation
The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation,
taking 150 ml of liquid medicine every morning and evening for 7 days.
Other: Placebo Treatment
Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo
every morning and evening for 7 days. All medications and placebo are packed identically
in packing bags with the same labeling form.
Inclusion Criteria:
- In the past two to three days, COVID-19 test was positive, accompanied by more than
one clinical symptom.
- 18 ≤ age ≤ 65, regardless of gender;
- Patients have good follow-up compliance.
Exclusion Criteria:
- Human immunodeficiency virus - 1 infection and malignant tumors; Active
cardiovascular, kidney, lung, liver, blood, digestive, neurological or psychiatric
diseases; Recent acute respiratory symptoms (within 4 weeks) .
- Any drug that may interfere with the evaluation (for example, other herbal products
such as Lianhua Qingwen, immunosuppressants, anticoagulants), or a history of
allergy or other adverse reactions to traditional Chinese medicine products.
- Pregnant or lactating women.
- Allergic constitution and allergy to multiple drugs.
- According to the judgment of the investigator, the subject suffers from any disease
that may endanger his safety or affect his compliance with the protocol, or other
conditions that are not suitable for the study.
First Affilicated Hospital of Xian Jiaotong University
Xi'an, Shanxi, China
Investigator: Zixian Du, master
Contact: 0086-15117288251
379880218@qq.com
Bingyin Shi
0086-13700298366
shibingy@126.com
Zixian Du, master
0086-15117288251
379880218@qq.com
Bingyin Shi, Study Chair
First Affilicated Hospital of Xian Jiaotong University